• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Acridone suppresses the proliferation of human breast cancer cells via ATP-binding cassette subfamily G member 2.吖啶酮通过ATP结合盒亚家族G成员2抑制人乳腺癌细胞的增殖。
Oncol Lett. 2018 Feb;15(2):2651-2654. doi: 10.3892/ol.2017.7583. Epub 2017 Dec 11.
2
Acridone-based antitumor agents: a mini-review.基于吖啶酮的抗肿瘤药物:一篇综述。
Anticancer Agents Med Chem. 2015;15(8):1012-25. doi: 10.2174/1871520615666150113104457.
3
Inhibition effects of acridone on the growth of breast cancer cells in vivo.阿魏酸在体内对乳腺癌细胞生长的抑制作用。
Eur Rev Med Pharmacol Sci. 2018 Apr;22(8):2356-2363. doi: 10.26355/eurrev_201804_14827.
4
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.厄洛替尼(特罗凯,OSI-774)可拮抗ATP结合盒转运体B成员1和ATP结合盒转运体G成员2介导的耐药性。
Cancer Res. 2007 Nov 15;67(22):11012-20. doi: 10.1158/0008-5472.CAN-07-2686.
5
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.拉帕替尼(泰立沙,GW572016)通过抑制ATP结合盒亚家族B成员1和G成员2的活性来逆转癌细胞中的多药耐药性。
Cancer Res. 2008 Oct 1;68(19):7905-14. doi: 10.1158/0008-5472.CAN-08-0499.
6
Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression.酰基辅酶 A 合成酶 4 参与涉及能量依赖型转运体表达调控的乳腺癌细胞系耐药。
Biochem Pharmacol. 2019 Jan;159:52-63. doi: 10.1016/j.bcp.2018.11.005. Epub 2018 Nov 9.
7
Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.人肝脏羧酸酯酶(hCE1m6)的转录靶向及抗BCRP短发夹RNA的同时表达增强了乳腺癌细胞对CPT-11的敏感性。
Anticancer Res. 2014 Nov;34(11):6345-51.
8
Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.达可替尼通过抑制 ABCG2 的药物外排功能,在体外和体内增强常规化疗药物的疗效。
J Exp Clin Cancer Res. 2018 Feb 20;37(1):31. doi: 10.1186/s13046-018-0690-x.
9
Phorbol ester TPA modulates chemoresistance in the drug sensitive breast cancer cell line MCF-7 by inducing expression of drug efflux transporter ABCG2.佛波酯TPA通过诱导药物外排转运体ABCG2的表达来调节药物敏感型乳腺癌细胞系MCF-7中的化学抗性。
Asian Pac J Cancer Prev. 2012;13(6):2979-84. doi: 10.7314/apjcp.2012.13.6.2979.
10
Downregulation of ATP-binding cassette subfamily C member 4 increases sensitivity to neoadjuvant radiotherapy for locally advanced rectal carcinoma.下调三磷酸腺苷结合盒亚家族 C 成员 4 可增加局部晚期直肠癌新辅助放化疗敏感性。
Dis Colon Rectum. 2013 May;56(5):600-8. doi: 10.1097/DCR.0b013e31827c2b80.

引用本文的文献

1
Acridone Derivatives from Inhibited Cancer Cell Proliferation through ERK Pathway.吖啶酮衍生物通过 ERK 通路抑制癌细胞增殖。
Molecules. 2022 Jun 16;27(12):3865. doi: 10.3390/molecules27123865.

本文引用的文献

1
Cancer drug resistance: an evolving paradigm.癌症耐药性:一个不断发展的范式。
Nat Rev Cancer. 2013 Oct;13(10):714-26. doi: 10.1038/nrc3599.
2
Drug rechallenge and treatment beyond progression--implications for drug resistance.药物再挑战与进展后治疗——耐药性的影响。
Nat Rev Clin Oncol. 2013 Oct;10(10):571-87. doi: 10.1038/nrclinonc.2013.158. Epub 2013 Sep 3.
3
Physicochemical interaction of antitumor acridinone derivatives with DNA in view of QSAR studies.基于定量构效关系(QSAR)研究的抗肿瘤吖啶酮衍生物与DNA的物理化学相互作用
Med Chem Res. 2011 Nov;20(8):1385-1393. doi: 10.1007/s00044-010-9487-y. Epub 2010 Nov 17.
4
Acridine and acridinones: old and new structures with antimalarial activity.吖啶和吖啶酮:具有抗疟活性的新旧结构
Open Med Chem J. 2011;5:11-20. doi: 10.2174/1874104501105010011. Epub 2011 Mar 9.
5
Natural and synthetic acridines/acridones as antitumor agents: their biological activities and methods of synthesis.天然和合成吖啶/吖啶酮作为抗肿瘤剂:它们的生物活性和合成方法。
Pharmacol Rep. 2011;63(2):305-36. doi: 10.1016/s1734-1140(11)70499-6.
6
Cytotoxicity studies of some novel fluoro acridone derivatives against sensitive and resistant cancer cell lines and their mechanistic studies.某些新型氟吖啶酮衍生物对敏感和耐药癌细胞系的细胞毒性研究及其机制研究。
Eur J Pharm Sci. 2011 Jul 17;43(4):217-24. doi: 10.1016/j.ejps.2011.04.010. Epub 2011 Apr 30.
7
Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy.发现天然产物调节剂以克服癌症化疗中的多药耐药性。
Curr Pharm Biotechnol. 2011 Apr;12(4):609-20. doi: 10.2174/138920111795163887.
8
Development of highly predictive 3D-QSAR CoMSIA models for anthraquinone and acridone derivatives as telomerase inhibitors targeting G-quadruplex DNA telomere.开发高预测性的 3D-QSAR CoMSIA 模型,用于作为端粒酶抑制剂的蒽醌和吖啶酮衍生物,针对 G-四链体 DNA 端粒。
J Mol Graph Model. 2010 Sep;29(2):229-39. doi: 10.1016/j.jmgm.2010.07.003. Epub 2010 Jul 15.
9
Global patterns of cancer incidence and mortality rates and trends.全球癌症发病率、死亡率的分布格局及变化趋势。
Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893-907. doi: 10.1158/1055-9965.EPI-10-0437. Epub 2010 Jul 20.
10
Metastatic behavior of breast cancer subtypes.乳腺癌亚型的转移行为。
J Clin Oncol. 2010 Jul 10;28(20):3271-7. doi: 10.1200/JCO.2009.25.9820. Epub 2010 May 24.

吖啶酮通过ATP结合盒亚家族G成员2抑制人乳腺癌细胞的增殖。

Acridone suppresses the proliferation of human breast cancer cells via ATP-binding cassette subfamily G member 2.

作者信息

Xu Licheng, Li Shuyan, Liang Zhi, Lin Haixia, Fu Rongzhan

机构信息

Department of Breast Surgery, Yantaishan Hospital, Yantai, Shandong 264000, P.R. China.

Department of Endocrinology, Yantai Yuhuangding Hospital, Yantai, Shandong 264000, P.R. China.

出版信息

Oncol Lett. 2018 Feb;15(2):2651-2654. doi: 10.3892/ol.2017.7583. Epub 2017 Dec 11.

DOI:10.3892/ol.2017.7583
PMID:29434987
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5777286/
Abstract

In the past decades, the tricyclic acridone ring system has become a focus of major research by medicinal chemists due to the biological significance of this moiety in drug design and discovery. Acridone has substantial bio-potential since it performs crucial functions, including antibacterial, antimalarial, antiviral and anti-neoplastic activities. However, the anticancer effect and the underlying mechanisms of acridone on breast cancer cells remains unclear. In the present study, the anti-tumor function and the underlying mechanisms of acridone were evaluated . Firstly, an MTT assay was used to evaluate the inhibitory effect of acridone. Subsequently, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was performed to investigate whether ATP binding cassette subfamily G member 2 (ABCG2) was associated with the function of acridone. Finally, western blotting was used to confirm the results of RT-qPCR. The present study demonstrated that acridone may decrease the proliferation of MDA-MB-231 cells dose-dependently. Further experiments revealed that acridone may downregulate the mRNA and protein expression levels of ABCG2, supporting the potential application of acridone in breast cancer treatment. These findings suggested that acridone is a potential agent in the treatment of human breast cancer.

摘要

在过去几十年中,由于三环吖啶酮环系统在药物设计与发现中的生物学意义,它已成为药物化学家主要研究的焦点。吖啶酮具有重要的生物潜力,因为它发挥着关键作用,包括抗菌、抗疟疾、抗病毒和抗肿瘤活性。然而,吖啶酮对乳腺癌细胞的抗癌作用及其潜在机制仍不清楚。在本研究中,评估了吖啶酮的抗肿瘤功能及其潜在机制。首先,使用MTT法评估吖啶酮的抑制作用。随后,进行逆转录定量聚合酶链反应(RT-qPCR),以研究ATP结合盒亚家族G成员2(ABCG2)是否与吖啶酮的功能相关。最后,使用蛋白质印迹法确认RT-qPCR的结果。本研究表明,吖啶酮可能剂量依赖性地降低MDA-MB-231细胞的增殖。进一步的实验表明,吖啶酮可能下调ABCG2的mRNA和蛋白质表达水平,这支持了吖啶酮在乳腺癌治疗中的潜在应用。这些发现表明,吖啶酮是治疗人类乳腺癌的一种潜在药物。